A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

Study acronym: EQUINOX
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 25 → 28 locations
    • Secondary endpoints: details revised at 2 of 2 entries
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).
Trial Details
NCT Number NCT07795814
Lead Sponsor Edgewise Therapeutics, Inc.
Conditions
(from sponsor)		 Heart Failure With Preserved Ejection Fraction
Related terms Heart Failure
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov